Optimata to collaborate with Teva Pharmaceutical Industries Ltd on clinical development of solid tumour cancer drugs.

Optimata Ltd has signed a collaboration agreement with Teva Pharmaceutical Industries Ltd focused on clinical development of drug candidates for solid tumour cancers. The agreement is intended to efficiently rescue and redirect the clinical development of discontinued drug candidates which have been shelved by their originators pharmaceutical companies, using Optimata's bio-simulation technology known as the Optimata Virtual Patient (OVP). Under the terms of the collaboration: Optimata will receive upfront payments, development milestones and royalty payments; in a separate agreement, Teva Pharmaceutical Industries Ltd has also made an undisclosed equity investment in Optimata Ltd. The …